Zepbound (tirzepatide) is FDA-approved for chronic weight management and — since December 2024 — for moderate-to-severe obstructive sleep apnea in adults with obesity. That second indication changes the appeal: for a patient with obstructive sleep apnea, Zepbound is treatment for a sleep-breathing disorder, and a plan exclusion written for "anti-obesity drugs" may not reach it. Identifying the correct indication is the single most important step.
This guide is the specific playbook for a Zepbound denial — the federal claims and appeal rules are the backdrop. What follows: the reasons your insurer gives for this category of denial, what federal and state law actually require your insurer to do, the written appeal step by step, the evidence to gather, and the deadlines that control the whole process. Rules are cited to the regulations and agency guidance that set them.